Overview
Empagliflozin (brand name Jardiance) is an SGLT2 inhibitor approved by the FDA in 2014 for type 2 diabetes. It has since received expanded indications for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (2016), heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023). Empagliflozin is widely regarded as the prototype SGLT2 inhibitor that established the cardiorenal benefits of this drug class.
The pivotal EMPA-REG OUTCOME trial in 2015 was the first major cardiovascular outcomes trial to show a significant reduction in cardiovascular death (relative risk reduction 38%) with a glucose-lowering agent, fundamentally changing the management of type 2 diabetes. Subsequent trials—EMPEROR-Reduced and EMPEROR-Preserved—extended these benefits to heart failure patients across the ejection-fraction spectrum, and EMPA-KIDNEY confirmed renal protection in CKD patients with or without diabetes.
Beyond its FDA indications, empagliflozin is being studied for longevity and metabolic resilience. Like canagliflozin, it produces mild caloric restriction through urinary glucose loss, elevates circulating ketones, and may activate AMPK and reduce mTOR signaling—mechanisms shared with established geroprotective interventions. Animal studies suggest modest lifespan and healthspan benefits, although direct human longevity data are lacking.
Empagliflozin is generally well tolerated and lacks the lower-limb amputation signal seen with canagliflozin. The main risks include genital mycotic infections, volume depletion, and rare but serious diabetic ketoacidosis (including euglycemic DKA).
Quick facts
- Mechanism
- Highly selective SGLT2 inhibitor with broad cardiorenal protection
- Primary use
- Type 2 diabetes; heart failure (HFrEF and HFpEF); chronic kidney disease
- Evidence
- strong
- FDA
- Approved
- Route
- Oral tablet, once daily in the morning
- Typical results
- HbA1c reductions of 0.7–0.8%; ~2–3 kg weight loss; ~35% reduction in cardiovascular death in EMPA-REG OUTCOME
Chemical information
Empagliflozin (C₂₃H₂₇ClO₇) is a longevity compound with a molecular weight of 450.91 g/mol. Its structural characteristics underpin its biological activity in longevity and anti-aging research.
How Empagliflozin works
Empagliflozin selectively inhibits SGLT2 in the proximal renal tubule, blocking approximately 90% of filtered glucose reabsorption and inducing urinary glucose excretion of 60–80 g/day along with osmotic and natriuretic effects. The resulting reductions in plasma volume, glucose, weight, and blood pressure are insulin-independent. Empagliflozin is the most SGLT2-selective drug in its class, with ~2,700-fold selectivity over SGLT1, producing minimal intestinal SGLT1 effects.
Cardiovascular benefits in EMPA-REG OUTCOME emerged within weeks, too early to be explained by glucose lowering, weight loss, or atherosclerosis modification. Current mechanistic understanding emphasizes hemodynamic effects (reduced preload and afterload), improved cardiac energetics (ketone body utilization by the failing heart), suppression of cardiac fibrosis and inflammation, and direct effects on cardiac sodium-hydrogen exchanger 1 (NHE1).
Renal protection arises from restoration of tubuloglomerular feedback: by delivering more sodium to the macula densa, SGLT2 inhibition constricts the afferent arteriole, lowers intraglomerular pressure, and reduces hyperfiltration—the central driver of progressive nephropathy. This mechanism explains why benefits extend to non-diabetic CKD populations in EMPA-KIDNEY.
Like other SGLT2 inhibitors, empagliflozin induces a mild ketogenic state and modest activation of cellular stress-response pathways (AMPK, sirtuins, autophagy) that overlap with caloric-restriction biology. These overlapping effects underpin growing interest in SGLT2 inhibitors as candidate gerotherapeutics.
- Highly selective SGLT2 inhibition: ~2,700× selectivity over SGLT1
- Cardiorenal hemodynamics: Reduces preload, intraglomerular pressure, and hyperfiltration
- Cardiac energetics: Shifts failing myocardium toward efficient ketone oxidation
- Class-leading outcomes data: First glucose-lowering drug to reduce CV mortality
- Geroprotective signaling: Mimics aspects of caloric restriction and AMPK activation
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Mass | 450.91 g/mol | Small-molecule oral SGLT2 inhibitor |
| Oral bioavailability | ~78% | High and reliable absorption |
| Tmax | ~1.5 hours | Take in the morning with or without food |
| Half-life | ~12.4 hours | Supports once-daily dosing |
| Metabolism | Primarily UGT2B7, UGT1A3, UGT1A8, UGT1A9 glucuronidation | Minimal CYP450 involvement |
| Elimination | Feces (~41%) and urine (~54%) | Not recommended if eGFR <20 (for diabetes); approved down to eGFR 20 for HF/CKD |
Dosing & administration
Empagliflozin dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for Empagliflozin is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Genital mycotic infections (more common in women)
- • Urinary tract infections
- • Increased urination
- • Thirst
- • Mild hypotension/dizziness at initiation
Serious / potential risks
- • Diabetic ketoacidosis, including euglycemic DKA
- • Volume depletion and acute kidney injury
- • Fournier's gangrene (rare necrotizing perineal infection)
- • Severe hypersensitivity (rare)
- • Hypoglycemia when combined with insulin or sulfonylureas
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Loop diuretics | Additive volume depletion | Reduce diuretic dose at initiation; monitor volume status |
| Insulin and sulfonylureas | Increased hypoglycemia risk | Lower insulin/sulfonylurea dose when starting empagliflozin |
| UGT inducers (rifampin) | May reduce empagliflozin exposure | Monitor glycemic response; no fixed dose adjustment |
| ACE inhibitors/ARBs | Additive cardiorenal protection | Standard combination in HF and CKD |
| Lithium | SGLT2 inhibitors may reduce lithium levels | Monitor lithium levels at initiation and dose changes |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Empagliflozin is a longevity compound with research interest in diabetes, heart failure, longevity. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying longevity and anti-aging research
- • Individuals interested in diabetes under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med (2015). doi: 10.1056/NEJMoa1504720 PMID: 26378978
- [2] Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med (2020). doi: 10.1056/NEJMoa2022190 PMID: 32865377
- [3] Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med (2021). doi: 10.1056/NEJMoa2107038 PMID: 34449189
- [4] The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med (2023). doi: 10.1056/NEJMoa2204233 PMID: 36331190